The Efficacy of Molecular Analysis in the Diagnosis of Bone and Soft Tissue Sarcoma: A 15-Year Mono-Institutional Study

Int J Mol Sci. 2022 Dec 30;24(1):632. doi: 10.3390/ijms24010632.

Abstract

The histological diagnosis of sarcoma can be difficult as it sometimes requires the combination of morphological and immunophenotypic analyses with molecular tests. A total of 2705 tissue samples of sarcoma consecutively collected from 2006 until 2020 that had undergone molecular analysis were assessed to evaluate their diagnostic utility compared with histological assessments. A total of 3051 molecular analyses were performed, including 1484 gene fusions tested by c/qRT-PCR, 992 gene rearrangements analysed by FISH, 433 analyses of the gene status of MDM2, 126 mutational analyses and 16 NGS analysis. Of the samples analysed, 68% were from formalin-fixed, paraffin-embedded tissue and 32% were from frozen tissue. C/qRT-PCR and FISH analyses were conclusive on formalin-fixed, paraffin-embedded tissue in 74% and 76% of samples, respectively, but the combination of the two methods gave us conclusive results in 96% and 89% of frozen and formalin-fixed, paraffin-embedded tissues, respectively. We demonstrate the utility of c/qRT-PCR and FISH for sarcoma diagnosis and that each has advantages in specific contexts. We conclude that it is possible to accurately predict the sarcoma subtype using a panel of different subtype-specific FISH probes and c/qRT-PCR assays, thereby greatly facilitating the differential diagnosis of these tumours.

Keywords: FISH; RT-PCR; formalin-fixed, paraffin-embedded tissue; frozen tissue; fusion transcript; molecular diagnostics; next-generation sequencing; qRT-PCR; sarcomas.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Formaldehyde
  • Humans
  • Paraffin Embedding
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sarcoma* / diagnosis
  • Sarcoma* / genetics
  • Sarcoma* / pathology

Substances

  • Biomarkers, Tumor
  • Formaldehyde

Grants and funding

This research received no external funding.